A Narrative Review of Current Evidence Supporting the Implementation of Electronic Patient-reported Outcome Measures in the Management of Chronic Diseases
Overview
Affiliations
An application of telemedicine of growing interest and relevance is the use of personal computers and mobile devices to collect patient-reported outcomes (PROs). PROs are self-reports of patients' health status without interpretation by anyone else. The tools developed to assess PROs are known as patient-reported outcomes measures (PROMs). The technological innovations that have led to an increased ownership of electronic devices have also facilitated the development of electronic PROMs (ePROMs). ePROMs are a conduit for telemedicine in the care of patients with chronic diseases. Various studies have demonstrated that the use of ePROMs in routine clinical practice is both acceptable and feasible with patients increasingly expressing a preference for an electronic mode of administration. There is increasing evidence that the use of electronic patient-reported outcome (ePROMs) could have significant impacts on outcomes valued by patients, healthcare providers and researchers. Whilst the development and implementation of these systems may be initially costly and resource-intensive, patient preferences and existing evidence to support their implementation suggests the need for continued research prioritisation in this area. This narrative review summarises and discusses evidence of the impact of ePROMs on clinical parameters and outcomes relevant to chronic diseases. We also explore recently published literature regarding issues that may influence the robust implementation of ePROMs for routine clinical practice.
Bech Vestergaard S, Roost M, Christiansen D, Schougaard L JMIR Form Res. 2025; 9():e58258.
PMID: 39815409 PMC: 11755678. DOI: 10.2196/58258.
Spronk I, Edgar D, Shoesmith V, Lansdorp C, Fear M, Wood F Eur Burn J. 2024; 5(4):369-388.
PMID: 39727909 PMC: 11675973. DOI: 10.3390/ebj5040033.
Longo R, Goetz C, Campitiello M, Plastino F, Egea J, Legros P BMC Cancer. 2024; 24(1):1568.
PMID: 39716103 PMC: 11665079. DOI: 10.1186/s12885-024-13312-4.
Meirte J, Tyack Z Eur Burn J. 2024; 3(2):290-308.
PMID: 39600000 PMC: 11575389. DOI: 10.3390/ebj3020025.
Rincon Bello A, Ion Titapiccolo J, Berdud Godoy I, Samaniego D, Ortego Perez S, Sobrino Perez A BMC Nephrol. 2024; 25(1):388.
PMID: 39482605 PMC: 11526659. DOI: 10.1186/s12882-024-03835-0.